New opportunities from the cancer metabolome

Clinical Chemistry

Volumn 59, Issue 1, 2013, Pages 138-146

  Aboud, Omran Abu ^a,b   Weiss, Robert H ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; EARLY DIAGNOSIS; FATTY ACID OXIDATION; GENE EXPRESSION; GENE MUTATION; GENOMICS; GLYCOLYSIS; HUMAN; IONIZING RADIATION; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; METABOLITE; METABOLOME; METABOLOMICS; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PERSONALIZED MEDICINE; PROTEOMICS; REVIEW; TRANSCRIPTOMICS;

EARLY DIAGNOSIS; HUMANS; INDIVIDUALIZED MEDICINE; METABOLOME; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872028171     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.184598     Document Type: Review

References (54)

1. Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrology 2011;8:22-33.
2. Calvani R, Miccheli A, Capuani G, Tomassini MA, Puccetti C, Delfini M, et al. Gut microbiome-derived metabolites characterize a peculiar obese urinary metabotype. Int J Obes 2010;34:1095-8.
3. Romick-Rosendale LE, Goodpaster AM, Hanwright PJ, Patel NB, Wheeler ET, Chona DL, Kennedy MA. NMR-based metabonomics analysis of mouse urine and fecal extracts following oral treatment with the broad-spectrum antibiotic enrofloxacin (Baytril). Magn Reson Chem 2009; 47(Suppl 1):S36-46.
4. Martin FP, Sprenger N, Montoliu I, Rezzi S, Kochhar S, Nicholson JK. Dietary modulation of gut functional ecology studied by fecal metabonomics. J Proteome Res 2010;9:5284-95.
5. Lindon JC, Nicholson JK. Analytical techniques for metabonomics and metabolomics, and multiomic information recovery. Trends Anal Chem 2008;27:194-204. (Pubitemid 351436617)
6. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008;455:1054-6.
7. German JB, Hammock BD, Watkins SM. Metabolomics: building on a century of biochemistry to guide human health. Metabolomics 2005; 1:3-9.
8. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007;35:D521-6. (Pubitemid 46056263)
9. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, et al. From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006;34:D354-7.
10. Fahy E, Sud M, Cotter D, Subramaniam S. LIPID MAPS online tools for lipid research. Nucleic Acids Res 2007;35:W606-12.
11. Taguchi R, Nishijima M, Shimizu T. Basic analytical systems for lipidomics by mass spectrometry in Japan. Methods Enzymol 2007;432:185-211.
12. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
13. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009;15:431-40.
14. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45. (Pubitemid 32173595)
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
16. Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, et al. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One 2011;6:e19823.
17. Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27:3889-900. (Pubitemid 351913639)
18. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-74. (Pubitemid 37279849)
19. Ganti S, Taylor S, Aboud OA, Yang J, Evans C, Osier M, et al. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. Cancer Res 2012;72:3471-9.
20. Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 2007; 363:185-95. (Pubitemid 46428214)
21. Zhang A, Sun H, Wang P, Han Y, Wang X. Modern analytical techniques in metabolomics analysis. Analyst 2012;137:293-300.
22. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33.
23. Ganti S, Weiss RH. Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol 2011;29:551-7.
24. Ganti S, Taylor S, Kim K, Hoppel CL, Guo L, Yang J, et al. Urinary acylcarnitines are altered in kidney cancer. Int.J Cancer 2011;130:2791-800.
25. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011;17:1094-100.
26. Godin-Ethier J, Pelletier S, Hanafi LA, Gannon PO, Forget MA, Routy JP, et al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol 2009;183:7752-60.
27. Bathen TF, Engan T, Krane J, Axelson D. Analysis and classification of proton NMR spectra of lipoprotein fractions from healthy volunteers and patients with cancer or CHD. Anticancer Res 2000; 20:2393-408. (Pubitemid 30614443)
28. Gribbestad IS, Sitter B, Lundgren S, Krane J, Axelson D. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res 1999;19:1737-46. (Pubitemid 29392730)
29. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed 2006;19:30-40. (Pubitemid 43250787)
30. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-6. (Pubitemid 38802433)
31. Bartella L, Thakur SB, Morris EA, Dershaw DD, Huang W, Chough E, et al. Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 2007;245:80-7. (Pubitemid 47417790)
32. Cheng LL, Wu C, Smith MR, Gonzalez RG. Non-destructive quantitation of spermine in human prostate tissue samples using HRMAS 1H NMR spectroscopy at 9.4 T. FEBS Lett 2001;494:112-6. (Pubitemid 32289382)
33. Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, et al. Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy. Magn Reson Med 2006;55:1257-64. (Pubitemid 43856762)
34. Maxwell RJ, Martinez-Perez I, Cerdan S, Cabanas ME, Arus C, Moreno A, et al. Pattern recognition analysis of 1H NMR spectra from perchloric acid extracts of human brain tumor biopsies. Magn Reson Med 1998;39:869-77. (Pubitemid 28237745)
35. Howe FA, Barton SJ, Cudlip SA, Stubbs M, Saunders DE, Murphy M, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003;49:223-32. (Pubitemid 36159858)
36. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006;66:10795-804. (Pubitemid 44876975)
37. Patterson AD, Li H, Eichler GS, Krausz KW, Weinstein JN, Fornace AJ Jr, et al. UPLC-ESI-TOFMS-based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem 2008;80:665-74. (Pubitemid 351206854)
38. Tyburski JB, Patterson AD, Krausz KW, Slavik J, Fornace AJ Jr, Gonzalez FJ, Idle JR. Radiation metabolomics. 1. Identification of minimally invasive urine biomarkers for gamma-radiation exposure in mice. Radiat Res 2008;170:1-14. (Pubitemid 351931182)
39. Tyburski JB, Patterson AD, Krausz KW, Slavik J, Fornace AJ Jr, Gonzalez FJ, Idle JR. Radiation metabolomics. 2. Dose- and time-dependent urinary excretion of deaminated purines and pyrimidines after sublethal gamma-radiation exposure in mice. Radiat Res 2009;172:42-57.
40. Lanz C, Patterson AD, Slavik J, Krausz KW, Ledermann M, Gonzalez FJ, Idle JR. Radiation metabolomics. 3. Biomarker discovery in the urine of gamma-irradiated rats using a simplified metabolomics protocol of gas chromatography-mass spectrometry combined with random forests machine learning algorithm. Radiat Res 2009;172:198-212.
41. Johnson CH, Patterson AD, Krausz KW, Lanz C, Kang DW, Luecke H, et al. Radiation metabolomics. 4. UPLC-ESI-QTOFMS-Based metabolomics for urinary biomarker discovery in gammairradiated rats. Radiat Res 2011;175:473-84.
42. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006;5:64.
43. Saude EJ, Adamko D, Rowe BH, Marrie T, Sykes BD. Variation of metabolites in normal human urine. Metabolomics 2007;3:439-51. (Pubitemid 350090674)
44. Saude EJ, Sykes BD. Urine stability for metabolomic studies: effects of preparation and storage. Metabolomics 2007;3:19-27. (Pubitemid 46453528)
45. Gika HG, Theodoridis GA, Wingate JE, Wilson ID. Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J Proteome Res 2007;6:3291-303. (Pubitemid 47310213)
46. Gika HG, Theodoridis GA, Wilson ID. Liquid chromatography and ultra-performance liquid chromatography-mass spectrometry fingerprinting of human urine: sample stability under different handling and storage conditions for metabonomics studies. J Chromatogr A 2008;1189:314-22.
47. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 2009;8:558-70.
48. Freis ED. Effect of treatment on morbidity and mortality in hypertension. Trans Assoc Life Insur Med Dir Am 1971;54:113-24.
49. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 2006;24:5601-8. (Pubitemid 46631341)
50. Yauch RL, Settleman J. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Curr Opin Genet Dev 2012;22:45-9.
51. Li Y, Maitah MY, Ahmad A, Kong D, Bao B, Sarkar FH. Targeting the Hedgehog signaling pathway for cancer therapy. Expert Opin Ther Targets 2012;16:49-66.
52. Bayet-Robert M, Morvan D, Chollet P, Barthomeuf C. Pharmacometabolomics of docetaxeltreated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res Treat 2010;120:613-26.
53. Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharma-cometabolomics- informed pharmacogenomics. Clin Pharmacol Ther 2011;89:97-104.
54. Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 2007;13:6993-7002. (Pubitemid 350276880)